Our results show that the effects of 1A-116, a drug designed to specifically inhibit the Rac1 signaling pathway by preventing its interaction with TIAM1, were also modulated by the circadian clock in LN229 cells in vitro and showed a time-of-day dependence in a glioma tumor model in vivo. Here, RAC1 is linked to neoplasm.